Aardvark Therapeutics (AARD) announced the appointments of key members of its leadership team, including Timothy Kieffer as chief scientific officer; Danny Villeneuve as chief commercial officer; Terrie Kellmeyer as senior VP, regulatory affairs and Christian Zapf as general counsel. Kieffer previously served as CSO at ViaCyte. Villeneuve most recently served as EVP, CCO for Ironshore Pharmaceuticals.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AARD:
- Aardvark Therapeutics Inc trading resumes
- Aardvark Therapeutics Inc trading halted, volatility trading pause
- Promising Future for Aardvark Therapeutics: Buy Rating Backed by Strong Pipeline and Financial Health
- Positive Outlook for Aardvark Therapeutics Amid Favorable Regulatory and Market Conditions
- Aardvark Therapeutics price target raised to $26 from $22 at BofA